1. Home
  2. PLG vs IRWD Comparison

PLG vs IRWD Comparison

Compare PLG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$2.75

Market Cap

250.1M

Sector

N/A

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

N/A

Current Price

$3.23

Market Cap

251.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLG
IRWD
Founded
2000
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.1M
251.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
PLG
IRWD
Price
$2.75
$3.23
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.34
AVG Volume (30 Days)
3.5M
2.5M
Earning Date
01-13-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
N/A
$338,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.01
P/E Ratio
N/A
$17.67
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.53
52 Week High
$3.36
$5.13

Technical Indicators

Market Signals
Indicator
PLG
IRWD
Relative Strength Index (RSI) 61.26 50.46
Support Level $2.45 $3.50
Resistance Level $2.95 $3.84
Average True Range (ATR) 0.22 0.27
MACD 0.02 -0.11
Stochastic Oscillator 67.52 20.78

Price Performance

Historical Comparison
PLG
IRWD

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: